SKIP000679 | |
SKIP ID | SKIP000679 |
Organism(En) | - |
Organism(Ja) | - |
Cell Type(En) | - |
Cell Type(Ja) | - |
Cell Tissue(En) | Lung |
Cell Tissue(Ja) | Lung |
Cell Origin | Normal |
Cell Name 1(En) | MRC5-RiPS-1.9 |
Cell Name 1(Ja) | MRC5-RiPS-1.9 |
Cell Name 2(En) | - |
Cell Name 2(Ja) | - |
Disease Name 1(Ja) | - |
ICD Code 1 | - |
Disease Name 1(En) | - |
OMIM1 | - |
Disease Name 2(Ja) | - |
ICD Code 2 | - |
Disease Name 2(En) | - |
OMIM 2 | - |
Disease Name 3(Ja) | - |
ICD Code 3 | - |
Disease Name 3(En) | - |
OMIM 3 | - |
Age | - |
Age Range | Fetus |
Sex | Male |
Race(En) | - |
Race(Ja) | - |
Genetic Diagnosis | -- |
Not Detected | No |
Description(En) | hiPS-cells derived from human fetal lung fibroblast cells (MRC-5 Line). They were derived using modified mRNAs coding reprogramming factors OCT4, SOX2, KLF4, c-MYC and LIN28 (OSKML) with molar concentrations in the ratio 3:1:1:1:1. |
Description(Ja) | 胎児肺線維芽細胞由来iPS細胞。 低酸素下でKlf4, c-Myc, Oct4, Sox2とLIN28を3:1:1:1:1の割合でコードした合成RNAを、線維芽細胞株に20日間毎日添加し、遺伝子を細胞へ導入した。 |
Cell Morphology | human ES-like |
Grade | Research Grade |
Vector | Other |
Transgene | OCT4 , SOX2 , KLF4 , c-MYC and LIN28 (OSKML) |
Adhesiveness | - |
Feeder | Yes |
Feeder Cell | γ -irradiated human neonatal fibroblast feeders (GlobalStem) |
Medium | DMEM/F12 + 20% KOSR + 5ng/ml FGF+(-)valproic acid (VPA)+a histone deacetylase inhibitor |
Genome Editing | - |
CO2 | - |
Mycoplasma | - |
Detection of Contaminants Mycoplasma | - |
Pluripotent Markers | - |
Pluripotent Markers Assay | - |
in vitro Differentiation | Yes |
in vitro Differentiation Assay | embryoid body formation |
in vivo Differentiation | - |
in vivo Differentiation Assay | - |
Other 1 Assay | Yes |
Other 1 Assay Method | qRT-PCR |
Other 2 Assay | - |
Other 2 Assay Method | - |
Other 3 Assay | - |
Other 3 Assay Method | - |
Karyotype | Yes |
Karyotype Assay | - |
Remaining Vector Detection | - |
Remaining Vector Detection Assay | - |
STR | - |
HLA | - |
Stem Cell Transcriptome analysis | - |
Stem Cell Transcriptome analysis Assay | - |
Author Name(En) | - |
Author Name(Ja) | - |
Author Organization(En) | - |
Author Organization(Ja) | - |
Author Contact Email | - |
PI Organization(En) | Immune Disease Institute, Program in Cellular and Molecular Medicine, Children's Hospital Boston |
PI Organization(Ja) | Immune Disease Institute, Program in Cellular and Molecular Medicine, Children's Hospital Boston |
PI Name(En) | Derrick J. Rossi |
PI Name(Ja) | Derrick J. Rossi |
PI Contact Email | - |
Availability | Information Only |
Provider Organization(En) | Immune Disease Institute, Program in Cellular and Molecular Medicine, Children's Hospital Boston |
Provider Organization(Ja) | Immune Disease Institute, Program in Cellular and Molecular Medicine, Children's Hospital Boston |
Provider Email | rossi[at]idi[dot]harvard[dot]edu |
Provider URL | - |
Ethical Statement(En) | - |
Ethical Statement(Ja) | - |
Terms of Use(En) | - |
Terms of Use(Ja) | - |
PubMed ID | 20888316 |
DOI | 10.1016/j.stem.2010.08.012 |
Title | Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. |
Authors | Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ |
Journal | Cell Stem Cell |
Year | 2010 |
Volume | 7 |
Issue | 5 |
Pages | 618-30 |
URL | http://www.ncbi.nlm.nih.gov/pubmed/20888316 |
Free input | - |
Note | - |